Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Biogen Advances Novel Alzheimer's Drug Despite Puzzling Trial Data

Biogen pushing tau drug forward despite Alzheimer’s study failure

BioPharma Dive1 min readAI-assisted summary
Editorial illustration for Biogen pushing tau drug forward despite Alzheimer’s study failure
Editorial illustration

Summary

Biogen is moving a new Alzheimer's disease treatment called BIIB080 into late-stage clinical trials. This medication uses a genetic technology known as an antisense oligonucleotide. In simple terms, this works like a targeted chemical roadblock. It is designed to block the specific genetic instructions that tell the body to produce too much tau, a protein that builds up and causes toxic effects inside and outside the brain cells of patients with Alzheimer's.

Delivering this therapy is an intensive process. Patients receive the drug through intrathecal injections, meaning the medicine is delivered directly into the fluid-filled space between the tissues covering the brain and the spinal cord. Biogen decided to advance the drug based on Phase 2 trial data that showed positive signs regarding biological markers and overall effectiveness.

However, the recent study results were conflicting and left experts with several questions. Normally in medicine, higher doses of a drug produce a stronger effect. BIIB080 showed an unexpected, non-linear dose response, meaning the clinical benefits did not cleanly scale up with higher doses. This puzzling outcome raises doubts about the actual strength of the drug's effectiveness.

Why it matters.

A successful treatment that targets the tau protein could be a major long-term victory for Alzheimer's patients, offering a pioneering way to attack the underlying mechanisms of cognitive decline. Millions of families are desperate for therapies that do more than just temporarily mask symptoms, and proving that a genetic medicine can alter the course of the disease would transform the neuroscience landscape.

Despite this potential, BIIB080 faces a difficult path to widespread use. Analysts caution that the company has provided limited details regarding the actual size of the cognitive benefit. Furthermore, the invasive nature of spinal injections means the current administration profile will likely need major improvements to be commercially viable for a large aging population. Until these clinical and practical hurdles are cleared, industry experts maintain a highly cautious outlook on the drug's future.

From the source

The story in numbers.

Placebo-controlled follow-up duration
76 weeks
Tested dose levels
60 mg and 115 mg
Dosing intervals
12 and 24 weeks
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗